Showing results (141-150 of 274) with videos related to
Sort By:
Pageof 28
Leukemia & Lymphoma|April 6, 2011
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials GroupRena Buckstein, John Kuruvilla, Neil Chua, et al.Pediatric Blood & Cancer|July 27, 2010
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group studyOrren Beaty, Stacey Berg, Susan Blaney, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumorsRamesh K Ramanathan, Merrill J Egorin, Charles Erlichman, et al.Seminars in Oncology|March 31, 2004
Molecular therapeutics: promise and challengesElise C Kohn, Yiling Lu, Hongwei Wang, et al.Gynecologic Oncology|May 3, 2011
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group StudyRobert S Mannel, Mark F Brady, Elise C Kohn, et al.Human Pathology|August 7, 2004
Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectivesDebra A Bell, Teri A Longacre, Jaime Prat, et al.Retina (Philadelphia, Pa.)|December 13, 2005
Effective transscleral delivery of two retinal anti-angiogenic molecules: carboxyamido-triazole (CAI) and 2-methoxyestradiol (2ME2)Lars P J Cruysberg, Alan J Franklin, Jason Sanders, et al.Cancer Chemotherapy and Pharmacology|September 19, 2020
Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration markerAnand Joshi, Jianxia Guo, Julianne L Holleran, et al.The Journal of Pathology|April 30, 2009
Genomic and phenotypic analysis reveals a key role for CCN1 (CYR61) in BAG3-modulated adhesion and invasionJareer N Kassis, Victoria M Virador, Elizabeth A Guancial, et al.Cancer Biology & Therapy|September 10, 2009
A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumorsNilofer Azad, Alyssa Perroy, Erin Gardner, et al.Pageof 28